Drugs / BNZ132-1-40
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT03239379 | Oct 2017 → Feb 2018 | — | Bioniz Therapeutics | Completed | No outcome recorded |
| Phase 1 | NCT03046459 | Nov 2016 → Jun 2017 | — | Bioniz Therapeutics | Completed | No outcome recorded |
| Phase 1/21 trial · 1 met primary | ||||||
| Phase 1/2 | NCT03239392 | Apr 2018 → Jun 2020 | T-cell large granular lymphocyte leukemia, primary cutaneous T-cell lymphoma | Bioniz Therapeutics | Completed | Met primary |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BNZ132-1-40 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03046459 ↗ |
| Action | Inhibit | “pegylated peptide inhibiting IL-2, IL-9 and IL-15” NCT03046459 ↗ |
| Modality | Peptide | “a novel peptide inhibitor of multiple cytokines in the IL-2 family” NCT03046459 ↗ |
| Route | Intravenous | “single doses of intravenous BNZ132-1-40 administered to healthy adult subjects” NCT03046459 ↗ |